Literature DB >> 2142243

Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.

H Modig1, S Borgström, I Nilsson, G Westman.   

Abstract

Thirteen postmenopausal women with advanced local or metastatic breast cancer were treated with the antiestrogen toremifene at a daily dose of 200 mg. All patients had failed previous treatment with different types of endocrine therapy and/or cytotoxic drugs. Objective response was only seen in one patient. Treatment was usually well tolerated but in three cases the drug had to be withdrawn due to side effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142243     DOI: 10.1016/0022-4731(90)90015-k

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  3 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.

Authors:  J U Mäenpää; S L Ala-Fossi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

3.  Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.

Authors:  L E Stenbygaard; J Herrstedt; J F Thomsen; K R Svendsen; S A Engelholm; P Dombernowsky
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.